Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA, RSV and Pfizer
Pfizer gets a leg up in RSV as FDA clears jab for all adults
A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival shots from GSK and Moderna, but it may not make much of a difference in the battle for market share.
FDA expands Pfizer’s RSV vaccine label to include all high-risk adults
Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.
FDA approves Pfizer's RSV shot Abrysvo for all at-risk adults
While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to determine how much advantage will be gained from the nod as the Centers for Disease Control (CDC) will have to sign off on Abvrysvo's use in the wider age group.
FDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 Years
Pfizer's RSV vaccine Abrysvo receives FDA approval for adults 18-59 at high risk, with extended use for pregnant individuals to safeguard infants from birth.
Pfizer Wins FDA Approval of RSV Vaccine for Broader Adult Population
Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age. Tuesday’s label expansion covers younger adults who are deemed at higher risk of RSV-related lower respiratory tract disease.
The FDA has approved Pfizer’s RSV vaccine Abrysvo for adults aged 18 to 59
The US pharma giant Pfizer recently announced that its respiratory syncytial virus (RSV) vaccine Abrysvo has received FDA approval in adults aged 18 to 59 who are at an increased risk of developing lower respiratory tract disease caused by RSV (RSV-LRTD).
US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.
Pfizer’s RSV vaccine cleared by FDA for use in some younger adults
Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people eligible for vaccination with the shot.
FDA OKs Pfizer’s RSV vaccine for some adults under 60
On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for people 18 to 59 who are more vulnerable to the virus.
New FDA approval for Pfizer’s RSV vaccine Abrysvo
The US Food and Drug Administration (FDA) yesterday approved Abrysvo (respiratory syncytial virus vaccine). Developed and marketed by US pharma giant Pfizer, the vaccine is now authorized for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV.
Pfizer Receives Expanded FDA Approval for RSV Vaccine
Abrysvo is the first vaccine for the respiratory syncytial virus that is indicated for adults younger than 50, the drugmaker said.
FiercePharma
1d
GSK answers Pfizer's RSV approval with data targeting matching nod in younger adults
“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...
3d
Is Pfizer's Attractive Valuation Enough to Invest in the Stock?
PFE's non-COVID drugs and potential contributions from new and newly acquired products have started to drive growth.
3d
Mixed Prospects and Uncertainty Lead to Hold Rating for Pfizer Amid COVID-19 Revenue Fluctuations
Analyst Mohit Bansal from Wells Fargo maintained a Hold rating on Pfizer (PFE – Research Report) and keeping the price target at $30.00.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback